Vivet Therapeutics is excited to announce two poster presentations at ESGCT 2025 in Sevilla, showcasing innovative advances in liver-directed gene therapy.
Catch us on Thursday, October 9th, from 14:00 to 15:30 CEST:
- Poster P0966: “Evaluation of Liver-Directed Gene Therapy in mice with Cerebrotendinous Xanthomatosis Pre-treated with Chenodeoxycholic Acid,” presented by our co-founder and scientific advisor, Gloria Gonzalez-Aseguinolaza.
- Poster P0972: “Liver-directed gene therapy results in long-term amelioration of progressive familial intrahepatic cholestasis type 2 in juvenile mice,” presented by Cristian Smerdou Picazo.
